Cirrus Therapeutics lands seed funding to advance gene therapy designed to prevent and reverse dry AMD by rejuvenating the retina. Ophthalmology focused biotech Cirrus Therapeutics has raised $11 million in seed financing to advance a gene therapy program that targets the underlying biology of dry a…
Vaccine selectively targets toxic forms of amyloid-beta that impair synaptic function and contribute to cognitive decline. Swedish biotech Alzinova has received Fast Track designation from the US FDA for its vaccine targeting Alzheimer’s disease. The news comes hot on the heels of the company securi…
Fractyl Health has revealed preclinical results for its gene therapy candidate RJVA-002, designed to encode both GIP and GLP-1 under a human insulin promoter to promote nutrient-responsive, pancreatic expression. According to the company, a single administration in a diet-induced obesity mouse model…
Serina Therapeutics, a clinical-stage biotechnology company, has drawn the first $5 million tranche of a potential $20 million financing agreement to advance its registrational trial of SER-252 for advanced Parkinson’s disease, according to the company. Subsequent funding tranches are linked to spec…
